跳至主要内容
临床试验/CTRI/2021/09/036500
CTRI/2021/09/036500已完成未知

A PROSPECTIVE STUDY TO COMPARE TUMOR RESPONSE AND TOXICITIES IN UNRESECTABLE NON SMALL CELL LUNG CANCERS TREATED BY CONCURRENT CHEMO RADIOTHERAPY USING TWO CHEMOTHERAPY REGIMENS SUCH AS CISPLATIN & ETOPOSIDE VS CARBOPLATIN & PACLITAXEL.

svims tirupati0 个研究点目标入组 34 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
34

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Histopathologically proven non small cell lung cancer patients.
  • 2.Unresectable lung cancers according to NCCN /BTS guidelines VI
  • 3.Patients with adequate hematologic parameters hemoglobin HB >=10g/dl, total white blood cell (WBC) >= 4000/mm3 and platelets >= 100,000/mm3 )and renal function >= 60ml/min.
  • 4. Patients with Eastern Cooperative Oncology Group (ECOG) performance status (0-2)
  • 5.Patients having age 18-65 years.
  • 6.Patients who are willing to give an approved informed consent

排除标准

  • Patients who already treated with surgery ,radiation therapy or chemotherapy for ca lung.
  • Patients with known distant metastases & malignant pleural effusion.
  • Patients with (ECOG) performance status 3- 4
  • Clinically significant cardiovascular comorbidities.
  • 5.Pregnant women and lactating mothers

研究者

发起方
svims tirupati

相似试验